Physician profile
Ashis Thampan
NPI 1770857955
$2,000.09
in general payments reported to CMS, 2019-2025
27 companies · $334 in 2025
The $334 reported for 2025 was more than what 87% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $227 · 2020: $158 · 2021: $255 · 2022: $306 · 2023: $499 · 2024: $221 · 2025: $334.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,048 · Education: $5.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,048.30 |
| Education | $5.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cranial Technologies, INC | $288.70 | 2019-2025 | Doc Band |
| Glaxosmithkline, LLC. | $206.06 | 2019-2025 | Bexsero, Rotarix, Pediarix |
| Sanofi Pasteur INC. | $197.32 | 2019-2025 | |
| Supernus Pharmaceuticals, INC. | $182.59 | 2023 | Qelbree |
| Merck Sharp & Dohme LLC | $156.81 | 2020-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Pfizer INC. | $134.24 | 2019-2024 | |
| Tris Pharma INC | $105.91 | 2019-2023 | Dyanavel Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $77.20 | 2020-2022 | |
| Verrica Pharmaceuticals INC. | $75.54 | 2024-2025 | Ycanth |
| Acadia Pharmaceuticals INC | $74.85 | 2025 | Daybue |
| Neurelis, INC. | $62.12 | 2021-2023 | Valtoco |
| Ironshore Pharmaceuticals INC. | $44.41 | 2022-2024 | |
| Sobi, INC | $41.93 | 2019-2020 | |
| Abbvie INC. | $39.41 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $37.65 | 2023 | Flumist Quadrivalent, Evusheld |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seqirus USA INC | $36.38 | 2022-2023 | Flucelvax Quadrivalent |
| Neos Therapeutics, Lp | $32.40 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $27.92 | 2025 | Zoryve |
| Ultragenyx Pharmaceutical INC. | $27.54 | 2020-2021 | |
| Corium, LLC | $27.19 | 2023 | Azstarys |
| Sanofi-Aventis U.S. LLC | $24.65 | 2025 | |
| Shire North American Group INC | $24.05 | 2019 | |
| Kyowa Kirin, INC. | $17.80 | 2025 | |
| Qiagen, LLC | $17.64 | 2023 | |
| Mission Pharmacal Company | $14.27 | 2019 | |
| Monteris Medical Corporation | $13.99 | 2024 | Neuroblate |
| Electromed, INC. | $11.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashis Thampan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.